Get started
Author

Shuji Ikegami

Observed name: 池上, 脩二
ORCID: 0000-0002-8576-539X
Observed ORCID: 0000-0002-8576-539X
OpenAlex ID: A5061076545
Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot study
2023 · Shuji Ikegami, Masanao Nakamura, et al. · Alimentary Pharmacology & Therapeutics · 37
Monoclonal Antibody Against Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function
2023 · Shuji Ikegami, Keiko Maeda, et al. · Inflammatory Bowel Diseases · 14
Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis
2022 · Keiko Maeda, Masanao Nakamura, et al. · Biomedicines · 7
PDF
Clinical factors influencing patency capsule excretion and confirmation in patients with intestinal patency
2024 · Shuji Ikegami, Takeshi Yamamura, et al. · Revista Española de Enfermedades Digestivas · 3
A case of intramural esophageal dissection caused by vomiting during barium esophagography
2025 · Takuya Ogiso, Shuji Ikegami, et al. · DEN Open · 1
PDF
Hepatic Artery Aneurysm Rupture After Double‐Balloon Endoscopy in Biliary Atresia
2024 · Shinya Yokoyama, Shuji Ikegami, et al. · United European Gastroenterology Journal
Monoclonal Antibody Against a Neoepitope of Caspase-Cleaved Mature Interleukin-18 Ameliorates Colitis in Mice and Improves Epithelial Barrier Function
2024 · 池上, 脩二, Ikegami, Shuji · Institutional Repositories DataBase (IRDB)
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors’ reply
2023 · Shuji Ikegami, Masanao Nakamura, et al. · Alimentary Pharmacology & Therapeutics
PDF
Works count: 8
Citation count: 62
H-index: 3
I10-index: 2
Year
Topic
Type